Hydroxyethylthio Vitamine K3
Based on 1 Customer Validation
Hydroxyethylthio Vitamin K3 is a Cdc25 phosphatase inhibitor, with IC50 values of 4.56 μM and 23.63 μM for Cdc25A and Cdc25B, respectively. Hydroxyethylthio Vitamin K3 can be used in tumor research.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度: 95.17%
- CAS 番号: 59147-84-1
- 分子式: C13H12O3S
- 分子量:248.30
-
保管条件:
Store at room temperature 3 years.
In solvent -80°C, 2 years , -20°C, 1 year
生物活性
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A549 | IC50 |
>10 μM
Compound: 6
|
Concentration required for 50% inhibition of growth in human lung carcinoma cell line was determined
Concentration required for 50% inhibition of growth in human lung carcinoma cell line was determined
|
[PMID: 12217364] |
| A549 | IC50 |
41.3 μM
Compound: 5
|
Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay
Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay
|
[PMID: 31563013] |
| Detroit 551 | IC50 |
8.17 μM
Compound: 6
|
Concentration required for 50% inhibition of growth in normal human embryonic skin fibroblast (Detroit551c) cell line was determined
Concentration required for 50% inhibition of growth in normal human embryonic skin fibroblast (Detroit551c) cell line was determined
|
[PMID: 12217364] |
| DU-145 | IC50 |
22.3 μM
Compound: PD8
|
Cytotoxicity against human DU145 cells assessed as growth inhibition after 72 hrs by MTS assay
Cytotoxicity against human DU145 cells assessed as growth inhibition after 72 hrs by MTS assay
|
[PMID: 23791367] |
| HepG2 | IC50 |
8.4 μM
Compound: 6
|
Concentration required for 50% inhibition of growth in human liver hepatoblastoma (Hep G2) cell line was determined
Concentration required for 50% inhibition of growth in human liver hepatoblastoma (Hep G2) cell line was determined
|
[PMID: 12217364] |
| HL-60 | IC50 |
9.3 μM
Compound: 5
|
Cytotoxicity against human HL60 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay
Cytotoxicity against human HL60 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay
|
[PMID: 31563013] |
| HT-29 | IC50 |
17.5 μM
Compound: PD8
|
Cytotoxicity against human HT-29 cells assessed as growth inhibition after 72 hrs by MTS assay
Cytotoxicity against human HT-29 cells assessed as growth inhibition after 72 hrs by MTS assay
|
[PMID: 23791367] |
| Jurkat | IC50 |
6.8 μM
Compound: 5
|
Cytotoxicity against human Jurkat cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay
Cytotoxicity against human Jurkat cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay
|
[PMID: 31563013] |
| LS174T | IC50 |
39.4 μM
Compound: 5
|
Cytotoxicity against human LS174T cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay
Cytotoxicity against human LS174T cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay
|
[PMID: 31563013] |
| MCF7 | IC50 |
30.9 μM
Compound: 5
|
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay
|
[PMID: 31563013] |
| MCF7 | IC50 |
5.19 μM
Compound: 6
|
Concentration required for 50% inhibition of growth in mammary gland breast adenocarcinoma (MCF-7) cell line was determined
Concentration required for 50% inhibition of growth in mammary gland breast adenocarcinoma (MCF-7) cell line was determined
|
[PMID: 12217364] |
| MDA-MB-231 | IC50 |
3.27 μM
Compound: PD8
|
Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 72 hrs by MTS assay
Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 72 hrs by MTS assay
|
[PMID: 23791367] |
| MES-SA | IC50 |
>10 μM
Compound: 6
|
Concentration required for 50% inhibition of growth in human multidrug resistance uterine sarcoma (MES-SA/Dx5 ) cell line was determined
Concentration required for 50% inhibition of growth in human multidrug resistance uterine sarcoma (MES-SA/Dx5 ) cell line was determined
|
[PMID: 12217364] |
| MES-SA | IC50 |
>10 μM
Compound: 6
|
Concentration required for 50% inhibition of growth in human uterine sarcoma (MES-SA) cell line was determined
Concentration required for 50% inhibition of growth in human uterine sarcoma (MES-SA) cell line was determined
|
[PMID: 12217364] |
| MKN-45 | IC50 |
5.16 μM
Compound: 6
|
Concentration required for 50% inhibition of growth in human stomach adenocarcinoma (MKN45) cell line was determined
Concentration required for 50% inhibition of growth in human stomach adenocarcinoma (MKN45) cell line was determined
|
[PMID: 12217364] |
| MONO-MAC-6 | IC50 |
6.3 μM
Compound: 5
|
Cytotoxicity against human MONO-MAC-6 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay
Cytotoxicity against human MONO-MAC-6 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay
|
[PMID: 31563013] |
| NPC-TW-039 | IC50 |
>10 μM
Compound: 6
|
Concentration required for 50% inhibition of growth in human nasopharyngeal carcinoma (TW-039) cell line was determined
Concentration required for 50% inhibition of growth in human nasopharyngeal carcinoma (TW-039) cell line was determined
|
[PMID: 12217364] |
| PBMC | IC50 |
13.3 μM
Compound: 5
|
Cytotoxicity against human PBMC cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay
Cytotoxicity against human PBMC cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay
|
[PMID: 31563013] |
| SW480 | IC50 |
5.14 μM
Compound: 6
|
Concentration required for 50% inhibition of growth in human colon adenocarcinoma (SW-480) cell line.
Concentration required for 50% inhibition of growth in human colon adenocarcinoma (SW-480) cell line.
|
[PMID: 12217364] |
| SW982 | IC50 |
19.3 μM
Compound: 5
|
Cytotoxicity against human SW982 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay
Cytotoxicity against human SW982 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay
|
[PMID: 31563013] |
| THP-1 | IC50 |
3.9 μM
Compound: 5
|
Cytotoxicity against human THP1 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay
Cytotoxicity against human THP1 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay
|
[PMID: 31563013] |
| U-937 | IC50 |
12.1 μM
Compound: 5
|
Cytotoxicity against human U937 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay
Cytotoxicity against human U937 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay
|
[PMID: 31563013] |
| WI-38 | IC50 |
7.37 μM
Compound: 6
|
Concentration required for 50% inhibition of growth in normal human lung fibroblast (WI-38 cell line) cell line was determined
Concentration required for 50% inhibition of growth in normal human lung fibroblast (WI-38 cell line) cell line was determined
|
[PMID: 12217364] |
化学情報
-
CAS 番号 59147-84-1
-
性状 Solid
-
分子量 248.30
-
分子式 C13H12O3S
-
Color Yellow to brown
-
SMILES
O=C1C(SCCO)=C(C)C(C2=C1C=CC=C2)=O
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Store at room temperature 3 years
In solvent -80°C 2 years -20°C 1 year
溶剤 & 溶解度
DMSO : 100 mg/mL (402.73 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (10.07 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (10.07 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
純度とドキュメンテーション
-
データシート (271 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Portuguese - PT (393 KB)
-
取扱説明書 (2659 KB)
参考文献
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 4.0273 mL | 20.1367 mL | 40.2734 mL | 100.6834 mL |
| 5 mM | 0.8055 mL | 4.0273 mL | 8.0547 mL | 20.1367 mL | |
| 10 mM | 0.4027 mL | 2.0137 mL | 4.0273 mL | 10.0683 mL | |
| 15 mM | 0.2685 mL | 1.3424 mL | 2.6849 mL | 6.7122 mL | |
| 20 mM | 0.2014 mL | 1.0068 mL | 2.0137 mL | 5.0342 mL | |
| 25 mM | 0.1611 mL | 0.8055 mL | 1.6109 mL | 4.0273 mL | |
| 30 mM | 0.1342 mL | 0.6712 mL | 1.3424 mL | 3.3561 mL | |
| 40 mM | 0.1007 mL | 0.5034 mL | 1.0068 mL | 2.5171 mL | |
| 50 mM | 0.0805 mL | 0.4027 mL | 0.8055 mL | 2.0137 mL | |
| 60 mM | 0.0671 mL | 0.3356 mL | 0.6712 mL | 1.6781 mL | |
| 80 mM | 0.0503 mL | 0.2517 mL | 0.5034 mL | 1.2585 mL | |
| 100 mM | 0.0403 mL | 0.2014 mL | 0.4027 mL | 1.0068 mL |